—We are gratified by the comments and intriguing speculation offered in the letters of Umeki and Maddox. It is interesting to note that Umeki suggests the possibility that the asthma therapy may directly affect gastrointestinal tract symptoms and that Maddox suggests that the gastrointestinal tract therapy may directly affect the asthma. This serves to illustrate the complex causal and management interrelationships between these two conditions.
Recent evidence concerning the late asthmatic reaction1 has emphasized that asthma is not only a bronchoconstrictive disease, but usually an inflammatory disease as well. If reflux-associated asthma (RAA) involves microaspiration or macroaspiration of refluxed acidic material, inflammation of the tracheobronchial mucosa is likely to be an important aspect of this condition. Systemic steroidal therapy may be expected to reduce the tracheobronchial inflammation and similarly decrease the bronchial hyperreactivity of RAA. Esophagitis, grossly and microscopically, was observed in a large proportion of our patients. Although we
Bergner A, Harper PC, Kaye MD. Treatment of Gastroesophageal Reflux-Induced Asthma: Steroids, ß2-Stimulants, and H2-Blockers-Reply. Arch Intern Med. 1987;147(5):997–1001. doi:10.1001/archinte.1987.00370050189040
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: